Anti-cancer screening of herbal drugs using cancer patient cells
Since the 1980s, a total of 174 new anti-cancer compounds have been approved for commercialization, of which 93 (53%) were natural products, or derived directly from plants. One of the most famous anti-cancer drugs, paclitaxel, used for the treatment of breast cancer, was isolated from the bark of Taxus Brevifolia. There is tremendous opportunity to systematically investigate promising plants and extracts for their anti-cancer activity and validate it rigorously in drug discovery campaigns. Even traditional plant-based medicines that have been in use for years need more data to claim anti-cancer activity. We provide a platform to pharma and biotech companies for screening their plant extracts and compounds directly on patient tumor-derived primary cancer cells (PDCs), in 2D and 3D assays, to confirm and compare their activity prior to testing in xenograft and PDX models.
Since the 1980s, a total of 174 new anti-cancer compounds have been approved for commercialization, of which 93 (53%) were natural products, or derived directly from plants. One of the most famous anti-cancer drugs, paclitaxel, used for the treatment of breast cancer, was isolated from the bark of Taxus Brevifolia. There is tremendous opportunity to systematically investigate promising plants and extracts for their anti-cancer activity and validate it rigorously in drug discovery campaigns. Even traditional plant-based medicines that have been in use for years need more data to claim anti-cancer activity. We provide a platform to pharma and biotech companies for screening their plant extracts and compounds directly on patient tumor-derived primary cancer cells (PDCs), in 2D and 3D assays, to confirm and compare their activity prior to testing in xenograft and PDX models.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Dose Response of Known Herbal Extracts in Brain Cancer primary PDCs
125
100
75
50
25
0
Ashwagandha derivative Internal Standard Turmeric derivative
IC50: 6.2 ug/ml
-25
0.1 1 10 100
Cpd conc [ug/ml]
IC50:
N1: 743 nM,
N2: 221 nM,
N3: 175nM
125
100
75
50
25
0
IC50: 12.5 ug/ml
0.1 1 10 100
Cpd conc [ug/ml]
Patient detail: PDC, SB 30771
Age/gender: 74 yr Male
Tissue Histology:
Glioblastoma
WHO Tumor grade: IV
Treatment details
available
1. Inhibition shown by Temozolomide (SOC) in above expt @ 300uM: 20 %
2. N1, N2 and N3 are 3 independent experiments performed on different days
3. There are a few publication that have done similar work with medicinal herbal extracts with
similar results as shown by us:
• IC50 value of an Ashwagandha extract in GBM primary cells: 4.2uM (J Neurooncol. 2016; 126: 253-64)
• IC50 of a turmeric extract in two GBM primary cells: 46 uM & 78 uM. (J Cancer Res Ther 2016;12(2)
11 July 2020
Sapien Biosciences
7
Change language